Navigation Links
GeNO LLC Announces Senior Management Appointment
Date:8/27/2013

WALTHAM, Mass., Aug. 27, 2013 /PRNewswire/ -- GeNO LLC, a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases, today announced that Kurt A. Dasse, Ph.D., currently serving as president and a member of the company's Board of Managers, has been appointed CEO of the Company.  Dr. David Fine will continue to serve GeNO as executive chairman and chief scientific officer.

"Dr. Dasse has significant international experience with the use of inhaled nitric oxide to minimize the risk of right heart failure following the treatment of patients undergoing the implantation of Left Ventricular Assist Devices (LVADs). This appointment will strengthen the company's focus on developing and obtaining regulatory approvals for its innovative and cost-effective platforms for generating nitric oxide therapy in the treatment of multiple diseases and conditions," said David Fine, GeNO founder and executive chairman. "I am thrilled to hand over the role of CEO to Kurt."

"I believe GeNO is well positioned to make a significant impact on the medical treatment of patients worldwide who suffer from pulmonary and cardiac diseases," said Dasse. "I am honored and excited to lead a highly talented group at GeNO committed to delivering the next generation of inhaled nitric oxide products, including a portable solution, designed to benefit a large patient population."

Dasse, who will continue to serve on the company's Board of Managers, has spent nearly 30 years researching and developing therapies for cardiopulmonary disorders, and has developed and commercialized devices and therapies for the treatment of heart, lung and renal failure. He joined GeNO as a member of the Board of Managers in 2007, and was appointed executive vice president in 2011 and president in 2012.

In 2001 Dasse co-founded Levitronix LLC, the developer of the CentriMag LVAD system, where he became president and CEO in 2006. Earlier in his career, Dasse was chief scientist and vice president of Thermo Electron Corporation's $700-million Biomedical Group. He was also one of the founding officers of Thermo Cardiosystems and played a key role in commercializing one of the first implantable ventricular assist systems for end-stage heart failure patients. Dasse received his doctorate in physiology from Boston University and his bachelor's degree in biology from the University of Massachusetts. He has written more than 100 journal articles and multiple book chapters, and holds numerous patents.

ABOUT GENO LLC

GeNO LLC is a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases.  GeNO is currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting.  GeNO's technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians and other end-users with a user-friendly solution.

CONTACT: Brian Heffron, bheffron@ctpboston.com
(781) 799-9568


'/>"/>
SOURCE GeNO LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sihuan Pharmaceutical Announces 2013 Interim Results
2. Echo Therapeutics Announces Management Changes
3. ConvaTec Announces 2013 Second Quarter Earnings Call
4. Sam Solakyan, CEO of Vital Imaging Announces purchase of cutting edge equipment
5. Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ
6. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
7. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
8. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
9. VirtualScopics Announces 1-for-10 Reverse Stock Split
10. Allscripts Announces Winners of the Open App Challenge
11. CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
Breaking Medicine Technology:
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the 2016 ... the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee Award ...
(Date:4/29/2016)... ... ... is the deadliest type of skin cancer. Although only about 1 percent of skin cancer ... than 10,000 people are expected to die of melanoma this year. The risk increases with ... the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may ...
(Date:4/29/2016)... ... , ... For those who skip meals occasionally (which is pretty much everyone), ... many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya Lawrence of ... show. Bonny and Lawrence noted that because proper nutrition, including water, provides energy during ...
(Date:4/29/2016)... N.J. (PRWEB) , ... April 29, 2016 , ... ... digital and print media enterprise focused entirely on patients with cancer, today announced ... California, was chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing ...
Breaking Medicine News(10 mins):